{
  "schemaVersion": 2,
  "eyebrow": "Hematology",
  "title": "Acute Promyelocytic Leukemia",
  "summary": "Acute promyelocytic leukemia is a hematologic emergency in which immediate presumptive treatment and aggressive coagulopathy support should precede definitive molecular confirmation, because early hemorrhagic death is preventable. Subsequent therapy is risk-adapted to presenting leukocyte count and requires specialized monitoring.",
  "seoDescription": "Point-of-care review of acute promyelocytic leukemia: emergency recognition, coagulopathy support, risk stratification, and treatment principles.",
  "clinicalQuestion": "How should clinicians recognize, stabilize, confirm, risk-stratify, and initiate treatment for suspected acute promyelocytic leukemia?",
  "specialty": "Hematology-Oncology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "acute promyelocytic leukemia",
    "APL",
    "ATRA",
    "coagulopathy",
    "differentiation syndrome",
    "PML-RARA"
  ],
  "keyTakeaways": [
    "Treat suspected APL as an immediate hematologic emergency because its aggressive coagulopathy can be life-threatening; prompt all-trans retinoic acid administration is central to initial management. [15]",
    "During initial coagulopathy management, maintain PT INR below approximately 1.5-2.0, fibrinogen above 100 mg/dL, and platelets above 30,000/µL with blood-product support. [15]",
    "Avoid invasive procedures, including central venous catheter placement, lumbar puncture, and leukapheresis, during the unstable coagulopathic presentation whenever possible. [15]",
    "Presenting WBC count of 10,000/µL or less defines standard-risk APL; WBC count above 10,000/µL defines high-risk disease. [15]"
  ],
  "sections": [
    {
      "id": "emergency-recognition",
      "eyebrow": "Immediate action",
      "heading": "Manage suspected APL before confirmation",
      "intro": "The early management priority is prevention of catastrophic bleeding.",
      "paragraphs": [
        "APL is a particularly aggressive acute myeloid leukemia subtype associated with life-threatening coagulopathy. Prompt administration of all-trans retinoic acid (ATRA) is a core initial intervention when APL is suspected, while diagnostic evaluation proceeds. [10][15]",
        "Coordinate urgent hematology involvement and obtain the diagnostic material needed to establish acute leukemia subtype and guide subsequent therapy. Acute leukemia work-up should include review of the CBC with differential and peripheral-blood smear; bone marrow aspirate and trephine biopsy, cytogenetic analysis, and molecular genetic testing inform diagnosis, prognosis, and treatment. [20][10]",
        "The supplied sources establish the emergency role of ATRA but do not provide a source-supported U.S. dosing regimen, confirmatory assay workflow, or molecular-response schedule. Verify current product labeling and institutional leukemia protocols before prescribing."
      ],
      "bullets": [
        "Obtain CBC with differential and have the peripheral smear reviewed promptly. [20]",
        "Obtain bone marrow aspirate and trephine biopsy with cytogenetic and molecular testing when clinically feasible. [10]",
        "Communicate neurologic findings, organomegaly, skin lesions, and suspected tumor masses to pathology because these findings are relevant to the acute leukemia diagnostic evaluation. [20]"
      ],
      "subsections": [],
      "table": {
        "caption": "Initial stabilization targets and procedural precautions in suspected APL. [15]",
        "columns": [
          "Clinical issue",
          "Action"
        ],
        "rows": [
          [
            "Coagulopathy",
            "Use blood-product transfusion support to keep PT INR below approximately 1.5-2.0. [15]"
          ],
          [
            "Hypofibrinogenemia",
            "Maintain fibrinogen above 100 mg/dL. [15]"
          ],
          [
            "Thrombocytopenia",
            "Maintain platelet count above 30,000/µL. [15]"
          ],
          [
            "Invasive procedures",
            "Avoid central-line placement, lumbar puncture, and leukapheresis during the coagulopathic presentation. [15]"
          ]
        ]
      }
    },
    {
      "id": "diagnostic-workup",
      "eyebrow": "Diagnosis",
      "heading": "Confirm APL while defining acute leukemia biology",
      "intro": "Diagnostic sampling should not delay emergency-directed management.",
      "paragraphs": [
        "AML diagnosis requires bone marrow aspirate and trephine biopsy assessment; cytogenetic and molecular genetic testing inform diagnostic classification, prognosis, and treatment selection. [10] For acute leukemia more broadly, the pathologist should review recent or concurrent CBC values, leukocyte differentials, and a peripheral smear. [20]",
        "APL-specific molecular confirmation is clinically consequential because treatment differs from other AML subtypes. The available sources identify molecular testing as part of AML evaluation but do not provide validated test characteristics, turnaround-time targets, or an assay-specific confirmatory strategy for suspected PML::RARA. Use the local hematopathology laboratory's urgent acute-leukemia pathway."
      ],
      "bullets": [
        "Send or ensure availability of CBC with differential and peripheral-blood smear for pathologist review. [20]",
        "Obtain marrow aspirate and core biopsy with cytogenetic and molecular studies. [10]",
        "Document neurologic examination and relevant extramedullary findings for the diagnostic team. [20]"
      ],
      "subsections": [],
      "table": {
        "caption": "Diagnostic components supported by acute leukemia and AML guidance. [10][20]",
        "columns": [
          "Component",
          "Clinical purpose"
        ],
        "rows": [
          [
            "CBC, differential, peripheral smear",
            "Establishes the hematologic presentation and supports morphologic evaluation of acute leukemia. [20]"
          ],
          [
            "Bone marrow aspirate and trephine biopsy",
            "Required for AML diagnostic assessment. [10]"
          ],
          [
            "Cytogenetic analysis",
            "Informs diagnosis, prognosis, and treatment planning in AML. [10]"
          ],
          [
            "Molecular genetic testing",
            "Informs diagnosis, prognosis, and treatment planning in AML. [10]"
          ]
        ]
      }
    },
    {
      "id": "risk-stratification",
      "eyebrow": "Risk",
      "heading": "Use presenting leukocyte count to classify treatment risk",
      "intro": "Presentation WBC count is a clinically useful APL risk discriminator.",
      "paragraphs": [
        "Presenting WBC count is a useful prognostic factor in APL. Standard-risk disease comprises low- and intermediate-risk categories with WBC count 10,000/µL or less; within this group, platelet count above or below 40 × 10^9/L distinguishes low from intermediate risk. High-risk APL is defined by presenting WBC count above 10,000/µL. [15]",
        "This classification should be documented at presentation before treatment-related changes in leukocyte count obscure the baseline risk category. The supplied evidence does not specify an exact treatment regimen by risk group; use contemporary institutional or specialty guidance for regimen selection."
      ],
      "bullets": [],
      "subsections": [],
      "table": {
        "caption": "APL risk categories based on presenting blood counts. [15]",
        "columns": [
          "Risk category",
          "Presenting WBC count",
          "Platelet distinction"
        ],
        "rows": [
          [
            "Low risk",
            "≤10,000/µL. [15]",
            "Platelets >40 × 10^9/L. [15]"
          ],
          [
            "Intermediate risk",
            "≤10,000/µL. [15]",
            "Platelets ≤40 × 10^9/L. [15]"
          ],
          [
            "High risk",
            ">10,000/µL. [15]",
            "Not required for high-risk classification. [15]"
          ]
        ]
      }
    },
    {
      "id": "treatment-principles",
      "eyebrow": "Therapy",
      "heading": "Transition from stabilization to specialized APL therapy",
      "intro": "Induction, consolidation, transplant, and maintenance decisions require disease- and patient-specific planning.",
      "paragraphs": [
        "AML treatment is generally organized into induction and consolidation phases, with hematopoietic stem-cell transplantation and/or maintenance used selectively. [10] In APL, management begins differently because prompt ATRA and correction of coagulopathy are prioritized at first suspicion. [15]",
        "Treatment planning should account for baseline APL risk, early bleeding risk, evolving leukocyte count, organ function, treatment tolerance, and access to leukemia-specialist care. FDA guidance recognizes that AML drug development and treatment indications may apply to individual phases including maintenance and transplantation preparative regimens, underscoring that these phases require distinct objectives and evidence. [2][3]",
        "The supplied sources do not provide source-supported doses or sequencing for arsenic trioxide, anthracycline-based therapy, cytoreductive therapy, corticosteroid prophylaxis or treatment for differentiation syndrome, transplantation, maintenance, or molecular surveillance. These decisions should follow current APL-specific protocols rather than extrapolation from non-APL AML regimens."
      ],
      "bullets": [
        "Do not defer emergency APL-directed management while awaiting complete cytogenetic or molecular results when clinical suspicion is high. [15]",
        "Reassess bleeding risk and transfusion targets repeatedly during the early coagulopathic period. [15]",
        "Use leukemia-specialist and institutional protocol support for definitive induction and post-remission planning because the supplied evidence does not specify regimen details. [10][15]"
      ],
      "subsections": [],
      "table": {
        "caption": "Treatment phases and their stated objectives in AML guidance. [2][10]",
        "columns": [
          "Phase",
          "Stated objective or role"
        ],
        "rows": [
          [
            "Induction",
            "A limited, usually intensive course intended to achieve complete remission. [2]"
          ],
          [
            "Consolidation",
            "A limited treatment course following induction. [2]"
          ],
          [
            "Transplantation or maintenance",
            "May be used in selected AML patients. [10]"
          ]
        ]
      }
    },
    {
      "id": "monitoring-complications",
      "eyebrow": "Monitoring",
      "heading": "Monitor coagulopathy and avoid iatrogenic bleeding",
      "intro": "Early supportive care is as time-sensitive as antileukemic treatment.",
      "paragraphs": [
        "The defining early complication emphasized in the available evidence is life-threatening coagulopathy. Monitor coagulation parameters, fibrinogen, and platelet count closely enough to sustain the recommended transfusion targets, escalating blood-product support when values fall outside target. [15]",
        "Avoid procedures that may precipitate bleeding during the coagulopathic presentation. Specifically, central-line placement, lumbar puncture, and leukapheresis should be avoided. [15] If an invasive procedure becomes unavoidable, individualize timing after hematology consultation and correction of coagulopathy; no procedural thresholds beyond the cited transfusion targets are provided in the supplied sources."
      ],
      "bullets": [
        "Trend PT INR and maintain it below approximately 1.5-2.0 with transfusion support. [15]",
        "Trend fibrinogen and maintain it above 100 mg/dL. [15]",
        "Trend platelet count and maintain it above 30,000/µL. [15]",
        "Defer nonessential central access, lumbar puncture, and leukapheresis. [15]"
      ],
      "subsections": [],
      "table": {
        "caption": "Early APL monitoring priorities. [15]",
        "columns": [
          "Measure or decision",
          "Target or action",
          "Rationale"
        ],
        "rows": [
          [
            "PT INR",
            "Maintain below approximately 1.5-2.0. [15]",
            "Supports correction of APL-associated coagulopathy. [15]"
          ],
          [
            "Fibrinogen",
            "Maintain above 100 mg/dL. [15]",
            "Supports correction of APL-associated coagulopathy. [15]"
          ],
          [
            "Platelet count",
            "Maintain above 30,000/µL. [15]",
            "Supports correction of APL-associated coagulopathy. [15]"
          ],
          [
            "Procedure need",
            "Avoid invasive procedures when possible. [15]",
            "Reduces procedural bleeding exposure during coagulopathy. [15]"
          ]
        ]
      }
    }
  ],
  "faq": [
    {
      "question": "What should trigger emergency management for suspected APL?",
      "answer": "APL should be treated as an emergency when clinically suspected because it is particularly aggressive and may produce life-threatening coagulopathy. Prompt ATRA administration and correction of coagulation abnormalities are emphasized while diagnostic evaluation proceeds. [10][15]"
    },
    {
      "question": "What transfusion targets are recommended during initial APL coagulopathy?",
      "answer": "The cited APL algorithm recommends maintaining PT INR below approximately 1.5-2.0, fibrinogen above 100 mg/dL, and platelets above 30,000/µL through blood-product transfusions. [15]"
    },
    {
      "question": "Should leukapheresis be used for leukocytosis in APL?",
      "answer": "The cited APL treatment algorithm advises avoiding leukapheresis, along with central-line placement and lumbar puncture, during the coagulopathic presentation. [15]"
    },
    {
      "question": "How is APL risk classified at diagnosis?",
      "answer": "Risk is based on presenting WBC count: WBC count of 10,000/µL or less is standard risk, with platelet count above versus at or below 40 × 10^9/L distinguishing low from intermediate risk; WBC count above 10,000/µL is high risk. [15]"
    },
    {
      "question": "What diagnostic studies should be obtained for suspected APL?",
      "answer": "Obtain CBC with differential and peripheral-smear review, and pursue bone marrow aspirate and trephine biopsy with cytogenetic and molecular testing. These studies support acute leukemia diagnosis and AML classification, prognosis, and treatment planning. [20][10]"
    }
  ],
  "references": [
    {
      "number": 1,
      "title": "Technical Specifications Acute Leukemias- ...",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/189220/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov"
    },
    {
      "number": 2,
      "title": "Guidance for Industry Acute Myeloid Leukemia",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/140821/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov"
    },
    {
      "number": 3,
      "title": "Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment | FDA",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-myeloid-leukemia-developing-drugs-and-biological-products-treatment-0",
      "authors": "www.fda.gov",
      "host": "www.fda.gov"
    },
    {
      "number": 4,
      "title": "761060Orig1s000 761060Orig2s000 - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761060Orig1s000Orig1Orig2s000ClinPharmR.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 5,
      "title": "This label may not be the latest approved by FDA. For current ...",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208573s023lbl.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 6,
      "title": "APPLICATION NUMBER: NDA 22-249/S-1 - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022249Orig1s001.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 7,
      "title": "[PDF] 1 This label may not be the latest approved by FDA. For current ...",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208447s019s020lbl.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 8,
      "title": "FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation | FDA",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation",
      "authors": "www.fda.gov",
      "host": "www.fda.gov"
    },
    {
      "number": 9,
      "title": "https://nctr-crs.fda.gov/fdalabel/services/spl/ ...",
      "detail": "nctr-crs.fda.gov",
      "url": "https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/08cf2861-2483-405d-a872-a88a5c235f9a/spl-doc",
      "authors": "nctr-crs.fda.gov",
      "host": "nctr-crs.fda.gov"
    },
    {
      "number": 10,
      "title": "Acute myeloid leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-us/274",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com"
    },
    {
      "number": 11,
      "title": "Acute lymphoblastic leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-us/273",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com"
    },
    {
      "number": 12,
      "title": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms | Blood Cancer Journal",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41408-025-01346-1",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 13,
      "title": "Management of patients with acute leukemia during the ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41409-020-0970-x",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 14,
      "title": "2025 European LeukemiaNet recommendations for the ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41375-025-02664-w",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 15,
      "title": "Acute promyelocytic leukemia current treatment algorithms",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41408-021-00514-3",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 16,
      "title": "Acute Leukemia: Diagnosis and Treatment",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0749208119301329",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 17,
      "title": "Leukemia Diagnostics - an overview",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/leukemia-diagnostics",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 18,
      "title": "Diagnosis and management of acute myeloid leukemia in ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0006497120493048",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 19,
      "title": "Contemporary Techniques for the Diagnosis of Acute ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0889858818305835",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 20,
      "title": "Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6338392",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 21,
      "title": "American Society of Hematology 2026 guidelines for treating newly diagnosed acute myeloid leukemia in older adults",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12993901",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 22,
      "title": "Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast]",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12235439",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 23,
      "title": "NCCN Clinical Practice Guidelines Acute myeloid leukemia",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22878824",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov"
    },
    {
      "number": 24,
      "title": "American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults - PubMed",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41321225",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "Technical Specifications Acute Leukemias- ...",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/189220/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov",
      "snippet": "therapy refers to leukemia treatments that are not prespecified as the study treatment in the protocol and that begin Study 151 Day 1 or later whether or not the participant is taken off study treatment. Record subsequent antileukemia therapies in CM in 152 accordance with the SDTM Implementation Gu",
      "score": 0.48952848
    },
    {
      "number": 2,
      "title": "Guidance for Industry Acute Myeloid Leukemia",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/140821/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov",
      "snippet": "as described in FDA's guidance.11 If the AML drug has 136 the potential to prolong the QT interval, the protocols should include appropriate 137 strategies for mitigation of QT prolongation, including a list of prohibited 138 concomitant medications associated with QT prolongation and/or more freque",
      "score": 0.4630806
    },
    {
      "number": 3,
      "title": "Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment | FDA",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acute-myeloid-leukemia-developing-drugs-and-biological-products-treatment-0",
      "authors": "www.fda.gov",
      "host": "www.fda.gov",
      "snippet": "Search for FDA   \nGuidance Documents\n\nThe purpose of this guidance is to assist sponsors in the clinical development of drugs and biological products for the treatment of acute myeloid leukemia (AML). Specifically, this guidance addresses FDA’s current thinking regarding the overall development prog",
      "score": 0.3655478
    },
    {
      "number": 4,
      "title": "761060Orig1s000 761060Orig2s000 - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761060Orig1s000Orig1Orig2s000ClinPharmR.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "No. The population PK analysis for the effect of age, sex, or renal/hepatic impairment did not indicate any need for dose adjustment of GO.\n3.3.4 What is the incidence (rate) of the formation of the anti-drug antibodies (ADA)? Do the ADAs have neutralizing activity?\nGO ADC was not measured in any of",
      "score": 0.534443
    },
    {
      "number": 5,
      "title": "This label may not be the latest approved by FDA. For current ...",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208573s023lbl.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "• Hepatic Impairment: Reduce the VENCLEXTA dose by 50% in patients with severe hepatic impairment. (2.7, 8.7) See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 11/2020 FULL PRESCRIBING INFORMATION: CONTENTS 1 INDICATIONS AND USAGE 1.1 Chronic Lymphocytic Leukemia/Small Lymphoc",
      "score": 0.5082762
    },
    {
      "number": 6,
      "title": "APPLICATION NUMBER: NDA 22-249/S-1 - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022249Orig1s001.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "have the potential to affect the exposure of bendamustine. (7) ---------------------------USE IN SPECIFIC POPULATIONS-------------------­ y Renal impairment: Do not use if CrCL is <40 mL/min. Use with caution in lesser degrees of renal impairment. (8.6) y Hepatic impairment: Do not use in moderate o",
      "score": 0.49362883
    },
    {
      "number": 7,
      "title": "[PDF] 1 This label may not be the latest approved by FDA. For current ...",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208447s019s020lbl.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "or antiplatelet drugs, consider interrupting these drugs and/or transfusion at a higher platelet count. • Resume ZEJULA at a reduced dose. a If myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) is confirmed, discontinue ZEJULA [see Warnings and Precautions (5.1, 5.2)]. 2.4 Dosage Adjustme",
      "score": 0.43223172
    },
    {
      "number": 8,
      "title": "FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation | FDA",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation",
      "authors": "www.fda.gov",
      "host": "www.fda.gov",
      "snippet": "The prescribing information includes warnings and precautions for differentiation syndrome, QTc interval prolongation, and embryo-fetal toxicity.\n\n## Recommended Dosage\n\nThe recommended ziftomenib dose is 600 mg taken orally once daily until disease progression or unacceptable toxicity.\n\n## Expedite",
      "score": 0.3869261
    },
    {
      "number": 9,
      "title": "https://nctr-crs.fda.gov/fdalabel/services/spl/ ...",
      "detail": "nctr-crs.fda.gov",
      "url": "https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/08cf2861-2483-405d-a872-a88a5c235f9a/spl-doc",
      "authors": "nctr-crs.fda.gov",
      "host": "nctr-crs.fda.gov",
      "snippet": "2 DOSAGE AND ADMINISTRATION    \n\n Capsules must be taken whole. ( 2.1)  Take consistently every morning at the same time on an empty stomach at least 1 hour before a meal or at least 2 hours after a meal. ( 2.1)  Avoid eating grapefruit or drinking grapefruit juice or alcohol. ( 2.1)  African-Americ",
      "score": 0.3813814
    },
    {
      "number": 10,
      "title": "Acute myeloid leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-us/274",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com",
      "snippet": "Many subtypes exist; the acute promyelocytic leukaemia (APL) subtype is particularly aggressive and may be associated with life-threatening coagulopathy.\n\nCharacteristically, abnormal myeloid blasts are present in the bone marrow (and in some cases the peripheral blood and extramedullary tissue) and",
      "score": 0.3999997
    },
    {
      "number": 11,
      "title": "Acute lymphoblastic leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-us/273",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com",
      "snippet": "open menu\n\nWhen viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.\n\n# Acute lymphoblastic leukaemia\n\nEpidemiology\n\nAetiology\n\nCase history\n\nApproach\n\nHistory and exam\n\nInvestigati",
      "score": 0.31242296
    },
    {
      "number": 12,
      "title": "Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms | Blood Cancer Journal",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41408-025-01346-1",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Article \n    PubMed \n    CAS \n    Google Scholar\n22. Röllig C, Kramer M, Schliemann C, Mikesch J-H, Steffen B, Krämer A, et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood. 2020;136:823–30.\n\n    Article \n    PubMed \n    Go",
      "score": 0.26023948
    },
    {
      "number": 13,
      "title": "Management of patients with acute leukemia during the ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41409-020-0970-x",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "by E Brissot · 2021 · Cited by 66 — In this case, the MRD should be very closely monitored, and maintenance therapy considered, especially in those cases. Patients with an ...Read more",
      "score": 0.5249554
    },
    {
      "number": 14,
      "title": "2025 European LeukemiaNet recommendations for the ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41375-025-02664-w",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "### Monitoring response to treatment\n\nBlood cell counts and differentials are required every 2 weeks until complete hematologic response (CHR) is achieved or more frequently in the event of hematologic toxicity. This applies not only to firstline treatment but also after switching TKI. Molecular mon",
      "score": 0.45856747
    },
    {
      "number": 15,
      "title": "Acute promyelocytic leukemia current treatment algorithms",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41408-021-00514-3",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "In addition to prompt ATRA administration, coagulopathy should be adequately corrected by keeping internationalized normalized ratio (INR) for PT at less than 1.5–2.0, fibrinogen greater than 100 mg/dL platelets greater than 30,000/µL through blood product transfusions. Invasive procedures, such as ",
      "score": 0.40260404
    },
    {
      "number": 16,
      "title": "Acute Leukemia: Diagnosis and Treatment",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0749208119301329",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "by LM Blackburn · 2019 · Cited by 93 — In a healthy adult, the ratio of red blood cells to white blood cell remains at 1000:1; and any value above this threshold is a characteristic, proliferative",
      "score": 0.63234437
    },
    {
      "number": 17,
      "title": "Leukemia Diagnostics - an overview",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/leukemia-diagnostics",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Table 2. European Group for the Immunologic Characterization of Leukemias (EGIL) scoring system for biphenotypic acute leukemias, 1998 version\n\n| Score | B Lineage | T Lineage | Myeloid Lineage |\n ---  --- |\n| 2 points | • Cytoplasmic CD79a • Cytoplasmic IgM • Cytoplasmic CD22 | • CD3 (cytoplasmic o",
      "score": 0.42262435
    },
    {
      "number": 18,
      "title": "Diagnosis and management of acute myeloid leukemia in ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0006497120493048",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the ",
      "score": 0.3227079
    },
    {
      "number": 19,
      "title": "Contemporary Techniques for the Diagnosis of Acute ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0889858818305835",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "by L Kass · 1988 · Cited by 7 — Leukemic blasts from patients with acute leukemia are identified most accurately by a combination of traditional panoptic stains, cytochemical stains,",
      "score": 0.2509591
    },
    {
      "number": 20,
      "title": "Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6338392",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "###### Recommendation 2.\n\nThe treating clinician should provide relevant physical examination and imaging findings or ensure that those results are readily accessible by the pathologist (_Recommendation_).\n\nNote: This includes, but is not limited to, neurologic examination findings and the presence ",
      "score": 0.76002824
    },
    {
      "number": 21,
      "title": "American Society of Hematology 2026 guidelines for treating newly diagnosed acute myeloid leukemia in older adults",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12993901",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "The panel included hematologists, geriatric specialists, community-based physicians, a clinical pharmacist, a nurse practitioner, oncologists, and patients. Clinician members had research expertise relevant to the guideline topic, including expertise in leukemia, epidemiology, palliative medicine, a",
      "score": 0.6334335
    },
    {
      "number": 22,
      "title": "Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast]",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12235439",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "4..Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. _\\_Ann Oncol\\__. 2020;24 Suppl 6:vi138–43. doi: 10.1016/j.annonc.2020.02.018  [DOI] [PubMed] [Google Scholar]\n   5..de Haas V, Ismaila N, Advan",
      "score": 0.57035583
    },
    {
      "number": 23,
      "title": "NCCN Clinical Practice Guidelines Acute myeloid leukemia",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22878824",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov",
      "snippet": "by MR O'Donnell · 2012 · Cited by 358 — The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML provide recommendations on the diagnostic evaluation and workup for AML, risk",
      "score": 0.47811517
    },
    {
      "number": 24,
      "title": "American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults - PubMed",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41321225",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov",
      "snippet": "Methods: ASH formed a multidisciplinary guideline panel, including patient representatives, that minimized bias from conflicts of interest. Clarity Research Group at McMaster University supported the guideline development process, including updating or performing systematic evidence reviews. The pan",
      "score": 0.47636098
    }
  ],
  "publishedAt": "2026-08-21T00:32:16.687780+00:00",
  "updatedAt": "2026-08-21T00:32:16.687780+00:00",
  "readingMinutes": 4,
  "slug": "acute-promyelocytic-leukemia"
}